Future epidemiological and economic impacts of universal influenza vaccines
JournalProceedings of the National Academy of Sciences of the United States of America
PublisherNational Academy of Sciences
MetadataShow full item record
AbstractThe efficacy of influenza vaccines, currently at 44%, is limited by the rapid antigenic evolution of the virus and a manufacturing process that can lead to vaccine mismatch. The National Institute of Allergy and Infectious Diseases (NIAID) recently identified the development of a universal influenza vaccine with an efficacy of at least 75% as a high scientific priority. The US Congress approved $130 million funding for the 2019 fiscal year to support the development of a universal vaccine, and another $1 billion over 5 y has been proposed in the Flu Vaccine Act. Using a model of influenza transmission, we evaluated the population-level impacts of universal influenza vaccines distributed according to empirical age-specific coverage at multiple scales in the United States. We estimate that replacing just 10% of typical seasonal vaccines with 75% efficacious universal vaccines would avert ∼5.3 million cases, 81,000 hospitalizations, and 6,300 influenza-related deaths per year. This would prevent over $1.1 billion in direct health care costs compared to a typical season, based on average data from the 2010–11 to 2018–19 seasons. A complete replacement of seasonal vaccines with universal vaccines is projected to prevent 17 million cases, 251,000 hospitalizations, 19,500 deaths, and $3.5 billion in direct health care costs. States with high per-hospitalization medical expenses along with a large proportion of elderly residents are expected to receive the maximum economic benefit. Replacing even a fraction of seasonal vaccines with universal vaccines justifies the substantial cost of vaccine development.
SponsorsThis work was supported by funding from NIH (Grant U01 GM087719), the Burnett and Stender Families endowment, and the Notsew Orm Sands Foundation.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85073072752&doi=10.1073%2fpnas.1909613116&partnerID=40&md5=5c19e30c2aa848ff98130ce5fd78a691; http://hdl.handle.net/10713/11170
- Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
- Authors: Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA
- Issue date: 2014
- Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic.
- Authors: Bartsch SM, Taitel MS, DePasse JV, Cox SN, Smith-Ray RL, Wedlock P, Singh TG, Carr S, Siegmund SS, Lee BY
- Issue date: 2018 Nov 12
- Net Costs Due to Seasonal Influenza Vaccination--United States, 2005-2009.
- Authors: Carias C, Reed C, Kim IK, Foppa IM, Biggerstaff M, Meltzer MI, Finelli L, Swerdlow DL
- Issue date: 2015
- Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
- Authors: Crépey P, Boiron L, Araujo RR, Lopez JG, Petitjean A, de Albuquerque Luna EJ
- Issue date: 2020 Sep 9
- From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
- Authors: Crépey P, Redondo E, Díez-Domingo J, Ortiz de Lejarazu R, Martinón-Torres F, Gil de Miguel Á, López-Belmonte JL, Alvarez FP, Bricout H, Solozabal M
- Issue date: 2020